Ointment for adults with plaque psoriasis
Part of Immune system & allergy, Skin clinical trials.
This trial tests an ointment called RSS0393 to see if it safely reduces the redness, thickness, and scaling of plaque psoriasis. It may help if you have mild-to-moderate psoriasis that is not well controlled with current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had plaque psoriasis for at least 6 months.
- Your psoriasis covers between 2% and 20% of your body surface area.
- Your psoriasis severity score is at least 2 on a standard scale.
- You have not used certain psoriasis treatments recently, such as topical creams, phototherapy, or biologics.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new ointment (called RSS0393) is safe and works well for young people with plaque psoriasis. It may help reduce the thick, scaly patches of skin caused by this condition.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This trial tests an ointment (RSS0393) for plaque psoriasis. It aims to see if the ointment reduces the size and severity of psoriasis patches and is safe to use.
This trial tests a new medication (HS-10374) taken by mouth to see if it is safe and effective for people with moderate to severe plaque psoriasis. It might help reduce the redness, scaling, and thickness of psoriasis plaques.
This trial tests an investigational drug, HB0017, in adults with moderate to severe plaque psoriasis. If you have had psoriasis for at least 6 months and have not used certain biologic treatments, you may be able to join.
This study tests an experimental oral tablet (CMS-D001) to see if it can safely and effectively reduce the severity of moderate to severe plaque psoriasis. It may be an easier treatment option compared to injections or light therapy.
Hear when a new Plaque Psoriasis Subjects trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.